Draft:Society for NeuroOncology

Humanetics Corporation to Present Clinical Trial Results at the Annual Meeting of the American Society for Radiation Oncology

Retrieved on: 
Thursday, May 28, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medical physics, Radioactivity, Radiobiology, Oncology, Branches of biology, Medicine, Physical sciences, Radiation therapy, Draft:Society for NeuroOncology, Radiation oncologist

Humanetics Corporation (Humanetics) today announced that an abstract reporting the results of a clinical trial of BIO 300 in non-small cell lung cancer patients undergoing radiochemotherapy has been selected for oral presentation at the annual meeting of the American Society for Radiation Oncology taking place virtually from October 25-28, 2020.

Key Points: 
  • Humanetics Corporation (Humanetics) today announced that an abstract reporting the results of a clinical trial of BIO 300 in non-small cell lung cancer patients undergoing radiochemotherapy has been selected for oral presentation at the annual meeting of the American Society for Radiation Oncology taking place virtually from October 25-28, 2020.
  • More than 3,300 abstracts were submitted to the premier international radiation oncology annual meeting, and Humaneticss abstract was one of only 280 selected for this highest level of oral presentation.
  • However, radiation therapy can cause unwanted side effects to otherwise healthy tissue surrounding the tumor or in the path of the radiation beam.
  • Humanetics acquired the rights to the drug and has active development programs ongoing in both oncology and for biodefense.

Community Oncology Alliance Elects Officers and New Board Members for 2020

Retrieved on: 
Wednesday, December 18, 2019
Community Oncology Alliance, Health, Draft:Society for NeuroOncology, Cancer and Leukemia Group B

COA has an Executive Committee of Officers that reports to a Board of Directors.

Key Points: 
  • COA has an Executive Committee of Officers that reports to a Board of Directors.
  • The Board and Committee are comprised of volunteer representatives from community oncology, who direct the management of COA by its Executive Director.
  • About the Community Oncology Alliance:
    The majority of Americans battling cancer receive treatment in the community oncology setting.
  • The Community Oncology Alliance (COA) advocates for community oncology and smart public policy that ensures the community cancer care system remains healthy and able to provide all Americans with access to local, quality, affordable cancer care.Learn more at www.CommunityOncology.org .

Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology

Retrieved on: 
Wednesday, November 20, 2019
Research, Other Health, General Health, Radiology, Pharmaceutical, Oncology, Medical devices, Clinical trials, Science, Biotechnology, FDA, Health, Other Science, Branches of biology, Organ systems, Medicine, Neurology, Medical physics, Oncology, RTT, Neuro-Oncology, Brain tumor, Radiation therapy, Blood–brain barrier, Draft:Society for NeuroOncology

Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields, including three oral presentations, will be featured at the 24th Annual Meeting of the Society for Neuro-Oncology (SNO) on Nov. 20 through Nov. 24 in Phoenix.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields, including three oral presentations, will be featured at the 24th Annual Meeting of the Society for Neuro-Oncology (SNO) on Nov. 20 through Nov. 24 in Phoenix.
  • Year after year, it is amazing to see the continued focus on Tumor Treating Fields at the SNO Annual Meeting, said Novocure CEO Asaf Danziger.
  • (Radiation Biology and DNA Repair/Basic Science)
    (Abstract #: NIMG-20) Evaluation of head segmentation quality for treatment planning of tumor treating fields in brain tumors.
  • (Health Outcome Measures/Clinical Research)
    (Abstract #: EXTH-02) The blood brain barrier (BBB) permeability is altered by Tumor Treating Fields (TTFields) in vivo.

KIYATEC Announces Addition of Capital Health as Clinical Site in Trial to Predict GBM Patient-Specific Response to Cancer Drugs Prior to Treatment

Retrieved on: 
Tuesday, August 13, 2019
Research, Clinical trials, Biotechnology, Pharmaceutical, Health, Oncology, Science, Draft:Society for NeuroOncology, Saint Thomas - Midtown Hospital

Capital Health is currently the only healthcare system in New Jersey, Pennsylvania and the New York City region enrolling GBM patients in the study.

Key Points: 
  • Capital Health is currently the only healthcare system in New Jersey, Pennsylvania and the New York City region enrolling GBM patients in the study.
  • Capital Health is committed to improving the health and well-being of our patients, while making the care we provide as personalized as possible.
  • The Center for Neuro-Oncology, part of Capital Institute for Neurosciences and Capital Health Cancer Center, is a referral center for the diagnosis and treatment of cancer involving the brain and spine.
  • In addition to providing advanced neuro-oncologic and neuroscience care, the Center participates in clinical trials to develop better ways to fight cancer.